An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms EV-202
- Sponsors Astellas Pharma; Astellas Pharma Global Development
Most Recent Events
- 10 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2024 Results (n=43) assessing antitumor activity in heavily pretreated non-squamous NSCLC and safety were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results assessing efficacy and safety of EV in multiple tumor-specific cohorts, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.